S&P 500 ends at record high on Greece hopes, as bonds drop
DJ: 18,047.58 +28.23 NAS: 4,899.27
+5.43 S&P: 2,100.34 +3.35
NEW YORK
(Reuters) - The S&P 500 ended above 2,100 at
another record high on Tuesday as optimism grew that a debt deal would be
reached with Greece and as bond prices sold off.
In a possible sign of
progress for Greece, a source
told Reuters the country
intends to ask for an extension of a loan agreement Wednesday. The
report follows a collapse of deal negotiations on Monday, which led to European
Union finance ministers pressuring the country to remain in an international
financial rescue program.
Late in the session,
though, broadcaster ZDF reported the German finance minister said an extension
was not up for debate.
U.S. Treasury debt
prices sold off, pushing benchmark 10-year note yields to seven-week peaks, on
expectations the Federal Reserve could bump up rates as early as June. Minutes
from the last Fed meeting are due Wednesday.
"We've seen more
of a risk-on trade," said Bucky Hellwig, senior vice president at BB&T
Wealth Management in Birmingham, Alabama. "Because bonds are so low
globally, it creates an interest in equities that perhaps the risk is worth taking
to get the higher return."
Among the S&P 500's biggest positives, shares of
Medical device maker Medtronic Plc (MDT.N), which last month completed the $49.9 billion purchase of
Ireland-based Covidien Plc, rose 3.7 percent at $78.07. Medtronic reported a
better-than-expected third-quarter profit, driven by solid growth in its
cardiac and vascular business.
The Dow Jones industrial average .DJI rose 28.23 points, or
0.16 percent, to 18,047.58, theS&P 500 .SPX gained 3.35 points,
or 0.16 percent, to 2,100.34, a record high. The NasdaqComposite .IXIC added 5.43 points, or
0.11 percent, to 4,899.27.
U.S.-listed shares of
the National Bank of Greece (NBG.N) ended up 1.2 percent at $1.63 after falling more than 13
percent earlier in the session.
Shares of Transocean
Ltd (RIG.N) recovered to close flat $19.05 a day after the company
slashed its dividend and said its chief executive stepped down.
Among decliners,
Celsus Therapeutics (CLTX.O) plummeted 81.4 percent to $1.15 after the company's lead
drug failed a mid-stage study. VBL Therapeutics Inc (VBLT.O) dropped 65.5 percent to $4.87 after it said it would stop
developing its experimental inflammatory drug to fight ulcerative colitis and
psoriasis.
A fragile Ukraine truce added uncertainty to the market. In eastern Ukraine, Pro-Russian rebels fought
their way into an encircled government bastion and were battling
street-to-street, all but
dashing hopes that a European-brokered peace deal would end months of conflict.
About 6.2 billion shares changed hands
on U.S. exchanges, below the 6.7 billion average for the last five sessions,
according to BATS Global Markets.
NYSE decliners
outnumbered advancers 1,776 to 1,337, for a 1.33-to-1 ratio; on the Nasdaq, 1,533 issues rose and 1,199
fell, a 1.28-to-1 ratio favoring advancers.
The S&P 500 posted 64 new 52-week highs and 2 new
lows; the Nasdaq Composite recorded 115 new highs and
22 new lows.
No comments:
Post a Comment